Sugi Predict

Sugi Predict / Compounds / SCHEMBL7007696

SCHEMBL7007696

SCHEMBL7007696

Nc1ccc2[nH]ccc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 8/20 0.41
▸ NCF1 P14598 1/20 0.41
▸ NOS2 P35228 1/20 0.41
▸ PLAU P00749 1/20 0.39
▸ NCK1 P16333 1/20 0.36
▸ MAOB P27338 2/20 0.36
▸ AHR P35869 4/20 0.34
▸ TRPA1 O75762 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ ITGB2 P05107 1/20 0.34
▸ ICAM1 P05362 1/20 0.34
▸ ITGAL P20701 1/20 0.34
▸ CA4 P22748 1/20 0.34
▸ CA6 P23280 1/20 0.34
▸ ADK P55263 1/20 0.34
▸ NR4A2 P43354 2/20 0.34
▸ CYP2A6 P11509 1/20 0.34
▸ F7 P08709 1/20 0.34
▸ LTA4H P09960 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31715595 0.98 BACE1 (0.40) BACE1NCF1NOS2PLAUNCK1
SCHEMBL30089364 0.77 AHR (0.43) MAOBAHRTRPA1CA1CA2
SCHEMBL421423 0.77 AHR (0.43) MAOBAHRTRPA1CA1CA2
SCHEMBL31038030 0.73 USP2 (0.43) MAOBAHRTRPA1CA1CA2
SCHEMBL3096846 0.73 MAOB (0.36) MAOBAHRTRPA1CA1CA2
SCHEMBL25011177 0.73 MAOB (0.36) MAOBAHRTRPA1CA1CA2
SCHEMBL29480781 0.73 MAPK1 (0.48) MAOBAHRTRPA1CA1CA2
SCHEMBL7016588 0.73 USP2 (0.43) MAOBAHRTRPA1CA1CA2
SCHEMBL23625710 0.73 APP (0.44) MAOBAHRTRPA1CA1CA2
SCHEMBL29548785 0.73 CYP1A2 (0.41) NOS2MAOBAHRTRPA1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 — — CN claimed
EP-4680607-A1 BICYCLIC UREAS AS KINASE INHIBITORS Incyte Corporation (US) 2026-01-21 — — EP disclosed
US-20240368153-A1 Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors Mirati Therapeutics, Inc. 2024-11-07 — — US disclosed
US-20240317744-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORPORATION 2024-09-26 — — US disclosed
WO-2024191996-A1 BICYCLIC UREAS AS KINASE INHIBITORS INCYTE CORPORATION (US) 2024-09-19 — — WO disclosed
US-20240294529-A1 6H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRIDINE DERIVATIVES FOR USE IN THERAPY SANOFI (FR) 2024-09-05 — — US disclosed
CN-118234727-A 6H-imidazo [1,2-a ] pyrrolo [2,3-e ] pyridine derivatives for use in therapy 赛诺菲 2024-06-21 — — CN disclosed
US-20240025924-A1 HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2024-01-25 — — US disclosed
US-20240025924-A1 HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2024-01-25 — — US disclosed
WO-2023278564-A1 AMINOPYRIDINE-BASED MTA-COOPERATIVE PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2023-01-05 — — WO disclosed
US-6150525-A Pyrrolo [3,2-b]pyridine processes and intermediates ELI LILLY AND COMPANY (US) 2000-11-21 — — US disclosed
US-5998622-A ANALGESICS; ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION ELI LILLY AND COMPANY (US) 1999-12-07 — — US disclosed
US-5919936-A 5-HT1F AGONIST INTERMEDIATES ELI LILLY AND COMPANY (US) 1999-07-06 — — US disclosed
WO-1999025708-A1 PYRROLO[3,2-b]PYRIDINE PROCESSES AND INTERMEDIATES ELI LILLY AND COMPANY (US) 1999-05-27 — — WO disclosed
EP-0916669-A2 Processes and intermediates for the preparation of Pyrrolo(3,2-b)pyridine ELI LILLY AND COMPANY (US) 1999-05-19 — — EP disclosed
EP-0916670-A2 Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists ELI LILLY AND COMPANY (US) 1999-05-19 — — EP disclosed
US-5905084-A 5-SUBSTITUTED-3-(PIPERIDIN-4-YL)- AND -3-(1,2,3,6-TETRAHYDROPYRIDIN-4-YL)PYRROLO(3,2-B)PYRIDINES; SIDE EFFECT REDUCTION; NERVOUS SYTEM AND PSYCHOLOGICAL DISORDERS ELI LILLY AND COMPANY (US) 1999-05-18 — — US disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 — — EP disclosed
US-5817671-A ANTISEROTONIN AGENT; ANALGESICS; MIGRAINE THERAPY; COMPOUND CONTAINING PYRROLO(3,2-B)PYRIDINE RING ELI LILLY AND COMPANY (US) 1998-10-06 — — US disclosed
EP-0842934-A1 5-HT1F agonists ELI LILLY AND COMPANY (US) 1998-05-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025924-A1 HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF BCKDK, CYP11B2, HSD17B7 BACE1 1830/4885NCF1 4322/4885NOS2 2773/4885
US-20240317744-A1 Bicyclic Ureas As Kinase Inhibitors JAK2, UCK2, ULK2 BACE1 4877/4885NCF1 1417/4885NOS2 948/4885
US-20240368153-A1 Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors PRMT5, PRMT1, PRMT3 BACE1 2838/4885NCF1 1355/4885NOS2 852/4885
US-20240294529-A1 6H-IMIDAZO[1,2-A]PYRROLO[2,3-E]PYRIDINE DERIVATIVES FOR USE IN THERAPY H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AKR1C3, CBR3 BACE1 4333/4885NCF1 1722/4885NOS2 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.